SAN DIEGO, CA -- (Marketwired) -- 05/30/13 -- Genelux Corporation, a clinical-stage biopharmaceutical company that develops vaccinia virus-based cancer therapies and companion diagnostics, today announced that it will present two posters at the American Society of Clinical Oncology (ASCO) 2013 Annual Meeting from May 31 - June 4 on its lead product candidate, GL-ONC1, an oncolytic (cancer-killing) viral therapy. The first poster, abstract 3098, "Phase I/II clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 in patients with unresectable, chemotherapy-resistant peritoneal carcinomatosis,"(1) will be presented by the study's lead investigator, Ulrich Lauer, MD, Department of Gastroenterology & Hepatology, Medical University Hospital, Tuebingen, Germany.
The second poster, abstract 3062, "Phase I clinical trial of a genetically modified and oncolytic vaccinia virus GL-ONC1 with green fluorescent protein imaging,"(2) will be presented by Dr. Khurum Khan on behalf of Prof. Johann de Bono, Royal Marsden Hospital and the Institute of Cancer Research, United Kingdom.
"GL-ONC1, our leading product candidate, has been well-tolerated and shown encouraging results in a number of Phase I, Ib and Phase I-II clinical trials in the United States and Europe against a number of solid tumor cancers. It is based on our novel product platform that delivers therapeutic and diagnostic constructs directly to tumors without harming healthy tissues or cells," said Dr. Aladar A. Szalay, founder and CEO of Genelux Corporation.
About Genelux Corporation
Headquartered in San Diego, California, Genelux Corporation is a privately held, clinical stage biopharmaceutical company dedicated to fundamentally changing the way in which cancer is diagnosed and treated. The company has developed a proprietary oncolytic vaccinia virus-based technology platform that can be engineered to insert specific therapeutic genes for delivery and amplification of anti-cancer proteins and RNAs into cancer cells without harming healthy cells. This platform includes a green fluorescent protein (GFP) as a bioluminescent diagnostic. The company is also incorporating advanced diagnostic deep-tissue imaging technologies into its viral platform to enable highly specific visualization of tumors and circulating cancer cells. GL-ONC1, the company's lead oncology product candidate, is an attenuated vaccinia virus (Lister strain) that is currently under evaluation in multiple human clinical trials in the US and Europe. For more information please visit www.genelux.com.
Genelux Forward-Looking Statement
Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.
(1) ClinicalTrials.gov identifier: NCT01443260
(2) ClinicalTrials.gov identifier: NCT009794131
Add to Digg Bookmark with del.icio.us Add to Newsvine
Most Popular Stories
- GE Healthcare Bringing Jobs to Massachusetts
- Apple Stock Bounces Back Big Time
- James Foley Killer Could Be ID'd Via Social Media, Voice Recognition
- Faith Groups Divest From Fossil Fuels
- James Foley Beheading Video Is Real Thing: White House
- Spiders Get Bigger, Reproduce Faster in Cities
- Entrepreneur Contest Announced in Idaho
- U.S. Existing Home Sales Rise 4th Month Straight
- Why BofA Won't Pay $17 Billion After All
- Notes From the July FOMC Meeting